Division for Biochemistry of Joint and Connective Tissue Diseases, Department of Orthopedics, University of Ulm, Ulm, Germany.
Institute of Clinical and Experimental Trauma-Immunology, University Hospital of Ulm, Ulm, Germany.
Osteoarthritis Cartilage. 2020 May;28(5):685-697. doi: 10.1016/j.joca.2020.01.004. Epub 2020 Jan 22.
Innate immune response and particularly terminal complement complex (TCC) deposition are thought to be involved in the pathogenesis of posttraumatic osteoarthritis. However, the possible role of TCC in regulated cell death as well as chondrocyte hypertrophy and senescence has not been unraveled so far and was first addressed using an ex vivo human cartilage trauma-model.
Cartilage explants were subjected to blunt impact (0.59 J) and exposed to human serum (HS) and cartilage homogenate (HG) with or without different potential therapeutics: RIPK1-inhibitor Necrostatin-1 (Nec), caspase-inhibitor zVAD, antioxidant N-acetyl cysteine (NAC) and TCC-inhibitors aurintricarboxylic acid (ATA) and clusterin (CLU). Cell death and hypertrophy/senescence-associated markers were evaluated on mRNA and protein level.
Addition of HS resulted in significantly enhanced TCC deposition on chondrocytes and decrease of cell viability after trauma. This effect was potentiated by HG and was associated with expression of RIPK3, MLKL and CASP8. Cytotoxicity of HS could be prevented by heat-inactivation or specific inhibitors, whereby combination of Nec and zVAD as well as ATA exhibited highest cell protection. Moreover, HS+HG exposition enhanced the gene expression of CXCL1, IL-8, RUNX2 and VEGFA as well as secretion of IL-6 after cartilage trauma.
Our findings imply crucial involvement of the complement system and primarily TCC in regulated cell death and phenotypic changes of chondrocytes after cartilage trauma. Inhibition of TCC formation or downstream signaling largely modified serum-induced pathophysiologic effects and might therefore represent a therapeutic target to maintain the survival and chondrogenic character of cartilage cells.
先天免疫反应,特别是末端补体复合物(TCC)的沉积,被认为与创伤后骨关节炎的发病机制有关。然而,TCC 在调节细胞死亡以及软骨细胞肥大和衰老中的可能作用迄今尚未被揭示,本研究首次使用体外人软骨创伤模型进行了研究。
软骨标本经受钝性冲击(0.59 J),并暴露于人血清(HS)和软骨匀浆(HG)中,同时加入或不加入不同的潜在治疗药物:RIPK1 抑制剂 Necrostatin-1(Nec)、半胱天冬酶抑制剂 zVAD、抗氧化剂 N-乙酰半胱氨酸(NAC)和 TCC 抑制剂金精三羧酸(ATA)和聚集素(CLU)。在 mRNA 和蛋白水平上评估细胞死亡和肥大/衰老相关标志物。
添加 HS 会导致软骨细胞 TCC 沉积显著增加,并在创伤后降低细胞活力。HG 的加入增强了这种效应,并与 RIPK3、MLKL 和 CASP8 的表达相关。HS 的细胞毒性可以通过热失活或特异性抑制剂来预防,其中 Nec 和 zVAD 的联合以及 ATA 表现出最高的细胞保护作用。此外,HS+HG 暴露会增强软骨创伤后 CXCL1、IL-8、RUNX2 和 VEGFA 的基因表达以及 IL-6 的分泌。
我们的研究结果表明,补体系统特别是 TCC 在软骨创伤后调节细胞死亡和软骨细胞表型变化中具有重要作用。抑制 TCC 的形成或下游信号转导在很大程度上改变了血清诱导的病理生理效应,因此可能成为维持软骨细胞存活和软骨生成特性的治疗靶点。